Feed MRK
MR

Merck & Co.

MRK · NYSE

$143.94 -0.54% (-$0.78)
1M +5.96%
Market Cap $357.4B
P/E Ratio 112.64x
Div. Yield 2.32%
ROE 6.60%

Bulios Fair Price

$142.57

0.9% downside

Current Price

$143.94

Undervalued Fair Value Overvalued

According to Bulios Fair Price, MRK is currently trading close to its fair value. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
5/9
Valuation
22 /100
Expensive
P/E 112.64x
PEG 2.95x
EV/EBITDA 29.22x
Growth
34 /100
Stable
EPS growth 8.43%
Book val. growth 4.58%
Rev. growth 3.08%
Profitability
78 /100
Strong
Gross margin 75.38%
FCF margin 24.19%
Net margin 4.78%
Quality
31 /100
Poor
ROIC 5.62%
Asset turnover 0.51x
ROE 6.60%
Debt
46 /100
Moderate
Debt/Equity 1.29x
Net debt/EBITDA 3.40x
Current ratio 1.32x
Stability
47 /100
Moderate
Beta 0.23x
Profitable years 6
Rev. volatility 3.15%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about MRK
Online

About the company

Merck & Co., Inc. (MRK) is a global pharmaceutical company with a long history and a broad portfolio of medicinal products. The company focuses on research, development, and manufacturing of drugs and biologics for various diseases, including cardiovascular diseases, oncological conditions, infectious diseases, diabetes, and other serious health conditions. Merck & Co. is known for its innovative pharmaceutical products, which are developed with an emphasis on safety and efficacy. The company has a strong research team that focuses on discovering new drugs and therapeutic approaches. Merck & Co. also collaborates with academic institutions and scientific partners to advance medicines and biotechnologies. The company has a global presence, and its products are distributed worldwide. Merck & Co., Inc. (MRK) shares are an attractive choice for investors who follow the pharmaceutical industry and seek investment opportunities in an established and innovative pharmaceutical company.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Robert Davis

Employees

74,000

Headquarters

Rahway

Upcoming events

15 SEP

Ex-Dividend

Ex-dividend date

2d
07 OCT

Dividend Payment

Payment date

24d
29 OCT

Earnings

Upcoming earnings report

46d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.